Immunovant
IMVT
31.77
-0.75
-2.31%
Immunovant
US · IMVT
#1790 by market cap
Listed 2017
31.77
-0.75
-2.31%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 8 analysts
Buy
Avg price target 48.43 +52.4%
Price target rangecurrent 31.77
Low37.00
Avg48.43
High66.00
Buy 75%
Hold 25%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-12 | J.P. Morgan | -- | Buy | 49.00 |
| 2026-11-10 | Wells Fargo | -- | Buy | 47.00 |
| 2026-11-10 | H.C. Wainwright | -- | Buy | 41.00 |
| 2026-11-09 | Wells Fargo | -- | Buy | 47.00 |
| 2026-11-09 | BofA Securities | -- | Buy | 46.00 |
| 2026-10-16 | Wells Fargo | -- | Buy | 45.00 |
| 2026-10-12 | BofA Securities | -- | Buy | 45.00 |
| 2026-09-26 | LifeSci Capital | -- | Buy | 53.00 |
| 2026-09-25 | Bernstein | -- | Hold | 37.00 |
| 2026-09-24 | Truist Financial | -- | Hold | -- |
| 2026-09-23 | LifeSci Capital | -- | Buy | 53.00 |
| 2026-09-23 | H.C. Wainwright | -- | Buy | 41.00 |
| 2026-09-21 | Piper Sandler | -- | Buy | 66.00 |
| 2026-08-11 | Stifel | -- | Buy | 57.00 |
| 2026-08-10 | H.C. Wainwright | -- | Buy | 41.00 |
| 2026-08-10 | J.P. Morgan | -- | Buy | 50.00 |
| 2026-08-07 | LifeSci Capital | -- | Buy | 53.00 |
| 2026-08-07 | Piper Sandler | -- | Buy | 66.00 |
| 2026-08-07 | BofA Securities | -- | Buy | 45.00 |
| 2026-08-07 | H.C. Wainwright | -- | Buy | 41.00 |
| 2026-08-07 | Oppenheimer | -- | Buy | 54.00 |
| 2026-08-04 | J.P. Morgan | -- | Buy | 50.00 |
| 2026-07-11 | LifeSci Capital | -- | Buy | 53.00 |
| 2026-07-09 | LifeSci Capital | -- | Buy | 53.00 |
| 2026-06-30 | Citi | -- | Buy | 61.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2027/Q2 | 2026-11-09 | -- | ±11.59% | +15.13% (beat) |
| 2027/Q1 | 2026-08-06 | -- | ±11.67% | +1.17% (in line) |
| 2026/Q4 | 2026-05-20 | -- | ±18.64% | +35.26% (beat) |
| 2026/Q3 | 2026-02-06 | -- | ±14.44% | +12.43% (in line) |
| 2026/Q2 | 2025-11-10 | -- | ±16.37% | +0.09% (in line) |
| 2025/Q2 | 2024-11-07 | -- | ±13.27% | -4.74% (in line) |
| 2022/Q4 | 2022-06-08 | -- | ±28.10% | -8.20% (in line) |
| 2022/Q1 | 2021-08-09 | -- | ±19.72% | +0.39% (in line) |
| 2021/Q4 | 2021-06-01 | -- | ±21.01% | -37.99% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Immunovant discussion 0 comments